Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer

摘要: Using our model to grow superficial human bladder cancer in the mouse bladder, we have found that polyamide compound, Syn3, when injected intravesically for 1 hour at mg/mL on two consecutive days, markedly increases rAd-beta-gal intravesical gene transfer and expression. This enhanced transgene expression was much greater than obtain by use of 22% ethanol, which had previously been shown increase adenoviral transfer, whereas little or no seen with exposure only rAd-beta-gal. beta-Galactosidase staining virtually every normal urothelial tumor cell present, including tumors express coxsackie-adenovirus receptors Syn3 present. High adenoviral-mediated also documented pig using a similar protocol. Therefore, may overcome limitations adequate and, combined an appropriate gene, could offer effective approach treatment perhaps even genetically altered precursor lesions.